Highly loaded, sustained-release microparticles of curcumin for chemoprevention

Journal of Pharmaceutical Sciences

Volumn 100, Issue 7, 2011, Pages 2599-2609

  Shahani, Komal ^a,b   Panyam, Jayanth ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cancer chemoprevention; Controlled delivery; Curcumin; Formulation; Microparticles; Poly(lactic glycolic) acid; Polymeric systems; Sustained release

Indexed keywords

CURCUMIN; CYCLOOXYGENASE 2; GLUTATHIONE TRANSFERASE; POLYGLACTIN; SOLVENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CRYSTALLIZATION; DRUG ACTIVITY; DRUG LIVER LEVEL; DRUG RELEASE; EMULSION; ENZYME ACTIVITY; EVAPORATION; FEMALE; IN VITRO STUDY; MICROTECHNOLOGY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; SUSTAINED RELEASE FORMULATION; VACUUM;

EID: 79955637308     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22475     Document Type: Article

References (54)

1. Aggarwal BB, Kumar A, Bharti AC. 2003. Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res 23(1A):363-398.
2. Strimpakos AS, Sharma RA. 2008. Curcumin: Preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 10(3):511-545.
3. Aggarwal BB, Sung B. 2009. Pharmacological basis for the role of curcumin in chronic diseases: An age-old spice with modern targets. Trends Pharmacol Sci 30(2):85-94.
4. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. 2008. Curcumin and cancer: An "old-age" disease with an "age-old" solution. Cancer Lett 267(1):133-164.
5. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. 2007. Bioavailability of curcumin: Problems and promises. Mol Pharm 4(6):807-818.
6. Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL, Howells L, Plummer S, Jukes R, Williams M, Steward WP, Gescher A. 2001. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 61(3):1058-1064.
7. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY. 2001. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21(4B):2895-2900.
8. Wang YJ, Pan MH, Cheng AL, Lin LI, Ho YS, Hsieh CY, Lin JK. 1997. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 15(12):1867-1876.
9. Shahani K, Swaminathan SK, Freeman D, Blum A, Ma L, Panyam J. 2010. Injectable sustained release microparticles of curcumin: A new concept for cancer chemoprevention. Cancer Res 70(11):4443-4452.
10. Freiberg S, Zhu XX. 2004. Polymer microspheres for controlled drug release. Int J Pharm 282(1-2):1-18.
11. Arshady R. 1991. Preparation of biodegradable microspheres and microcapsules: 2. Polylactides and related polyesters. J Control Release 17(1):1-21.
12. Bodmeier R, McGinity JW. 1987. The preparation and evaluation of drug-containing poly(dl-lactide) microspheres formed by the solvent evaporation method. Pharm Res 4(6):465-471.
13. Yallapu MM, Gupta BK, Jaggi M, Chauhan SC. 2010. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interface Sci 351(1):19-29.
14. Anand P, Nair HB, Sung B, Kunnumakkara AB, Yadav VR, Tekmal RR, Aggarwal BB. 2010. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol 79(3):330-338.
15. Mukerjee A, Vishwanatha JK. 2009. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res 29(10):3867-3875.
16. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MN. 2009. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci 37(3-4):223-230.
17. Wang YM, Sato H, Horikoshi I. 1997. Preparation and characterization of poly(lactic-co-glycolic acid) microspheres for targeted delivery of a novel anticancer agent taxol. Chem Pharm Bull (Tokyo) 44(10):1935-1940.
18. Tonnesen HH, Masson M, Loftsson T. 2002. Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: Solubility, chemical and photochemical stability. Int J Pharm 244(1-2):127-135.
19. Okada H. 1997. One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv Drug Deliv Rev 28(1):43-70.
20. Suzuki K, Price JC. 1985. Microencapsulation and dissolution properties of a neuroleptic in a biodegradable polymer, poly(d, l-lactide). J Pharm Sci 74(1):21-24.
21. Zhang P, Chen L, Gu W, Xu Z, Gao Y, Li Y. 2007. In vitro and in vivo evaluation of donepezil-sustained release microparticles for the treatment of Alzheimer's disease. Biomaterials 28(10):1882-1888.
22. Tsung MJ, Burgess DJ. 2001. Preparation and characterization of gelatin surface modified PLGA microspheres. AAPS PharmSci 3(2):E11.
23. Mao S, Shi Y, Li L, Xu J, Schaper A, Kissel T. 2008. Effects of process and formulation parameters on characteristics and internal morphology of poly(d, l-lactide-co-glycolide) microspheres formed by the solvent evaporation method. Eur J Pharm Biopharm 68(2):214-223.
24. Conti B, Genta I, Modena T, Pavanetto F. 1995. Investigation on process parameters involved in polylactide-co-glycolide microspheres preparation. Drug Dev Ind Pharm 21:615-622.
25. Cavalier M, Benoit JP, Thies C. 1986. The formation and characterization of hydrocortisone-loaded poly((+/-)-lactide) microspheres. J Pharm Pharmacol 38(4):249-253.
26. Rosilio V, Benoit JP, Deyme M, Thies C, Madelmont G. 1991. A physicochemical study of the morphology of progesterone-loaded microspheres fabricated from poly(D, L-lactide-co-glycolide). J Biomed Mater Res 25(5):667-682.
27. Tice TR, Gilley RM. 1985. Preparation of injectable controlled-release microcapsules by a solvent-evaporation process. J Control Release 2:343-352.
28. McGinity JW, O'Donnell PB. 1997. Preparation of microspheres by the solvent evaporation technique. Adv Drug Deliv Rev 28(1):25-42.
29. Bodmeier R, McGinity JW. 1988. Solvent selection in the preparation of poly (DL-lactide) microspheres prepared by the solvent evaporation method. Int J Pharm 43:179-186.
30. Izumikawa S, Yoshikawa S, Aso Y, Takeda Y. 1991. Preparation of poly (l-lactide) microspheres of different crystalline morphology and effect of crystalline morphology on drug release rate. J Control Release 15:133-140.
31. Chung TW, Huang YY, Liu YZ. 2001. Effects of the rate of solvent evaporation on the characteristics of drug loaded PLLA and PDLLA microspheres. Int J Pharm 212(2):161-169.
32. Miyazaki Y, Onuki Y, Yakou S, Takayama K. 2006. Effect of temperature-increase rate on drug release characteristics of dextran microspheres prepared by emulsion solvent evaporation process. Int J Pharm 324(2):144-151.
33. Yang CY, Tsay SY, Tsiang RC. 2001. Encapsulating aspirin into a surfactant-free ethyl cellulose microsphere using non-toxic solvents by emulsion solvent-evaporation technique. J Microencapsul 18(2):223-236.
34. Bodmeier R, McGinity JW. 1987. Polylactic acid microspheres containing quinidine base and quinidine sulphate prepared by the solvent evaporation technique. II. Some process parameters influencing the preparation and properties of microspheres. J Microencapsul 4(4):289-297.
35. Wischke C, Schwendeman SP. 2008. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int J Pharm 364(2):298-327.
36. Johansen P, Men Y, Audran R, Corradin G, Merkle HP, Gander B. 1998. Improving stability and release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives. Pharm Res 15(7):1103-1110.
37. Coombes AG, Scholes PD, Davies MC, Illum L, Davis SS. 1994. Resorbable polymeric microspheres for drug delivery-production and simultaneous surface modification using PEO-PPO surfactants. Biomaterials 15(9):673-680.
38. Boisdron-Celle M, Menei P, Benoit JP. 1995. Preparation and characterization of 5-fluorouracil-loaded microparticles as biodegradable anticancer drug carriers. J Pharm Pharmacol 47(2):108-114.
39. Wakiyama N, Juni K, Nakano M. 1981. Preparation and evaluation in vitro of polylactic acid microspheres containing local anesthetics. Chem Pharm Bull (Tokyo) 29(11):3363-3368.
40. Jalil R, Nixon JR. 1990. Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: Problems associated with preparative techniques and release properties. J Microencapsul 7(3):297-325.
41. Pan MH, Huang TM, Lin JK. 1999. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 27(4):486-494.
42. Zidan AS, Sammour OA, Hammad MA, Megrab NA, Hussain MD, Khan MA, Habib MJ. 2006. Formulation of anastrozole microparticles as biodegradable anticancer drug carriers. AAPS PharmSciTech 7(3):61.
43. Sinko PJ, Martin AN. 2005. Physical pharmacy-physical chemical principles in the pharmaceutical sciences. 5th ed.: Lippincott Williams & Wilkins, Philadelphia.
44. Turk M, Lietzow R. 2004. Stabilized nanoparticles of phytosterol by rapid expansion from supercritical solution into aqueous solution. AAPS PharmSciTech 5(4):e56.
45. Attwood D, Ktistis G, McCormick Y, Story MJ. 1989. Solubilization of indomethacin by polysorbate 80 in mixed water-sorbitol solvents. J Pharm Pharmacol 41(2):83-86.
46. Alexis AF. 2005. Factors affecting the degradation and drug release mechanism of poly(lactic) acid and poly [(lactic acid)-co-(glycolic acid)]. Polymer Int 54:36-46.
47. Jamshidi K, Hyon SH, Ikada Y. 1988. Thermal characterization of polylactides. Polymer 29:2229-2234.
48. Cohen S, Yoshioka T, Lucarelli M, Hwang LH, Langer R. 1991. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm Res 8(6):713-720.
49. Igartua M, Hernandez RM, Esquisabel A, Gascon AR, Calvo MB, Pedraz JL. 1997. Influence of formulation variables on the in-vitro release of albumin from biodegradable microparticulate systems. J Microencapsul 14(3):349-356.
50. Jeffery H, Davis SS, O'Hagan DT. 1993. The preparation and characterization of poly(lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique. Pharm Res 10(3):362-368.
51. Sharma RA, Manson MM, Gescher A, Steward WP. 2001. Colorectal cancer chemoprevention: Biochemical targets and clinical development of promising agents. Eur J Cancer 37(1):12-22.
52. Sharma RA. 2002. Translational medicine: Targetting cyclo-oxygenase isozymes to prevent cancer. QJM 95(5):267-273.
53. Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, Farrow S, Howells L. 1999. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 18(44):6013-6020.
54. Sharma RA, Ireson CR, Verschoyle RD, Hill KA, Williams ML, Leuratti C, Manson MM, Marnett LJ, Steward WP, Gescher A. 2001. Effects of dietary curcumin on glutathione S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels. Clin Cancer Res 7(5):1452-1458.